EWP
CORT icon

Elevation Wealth Partners’s Corcept Therapeutics CORT Stock Holding History

Elevation Wealth Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Buy
176
+30
+21% +$1.81K ﹤0.01% 669
2026
Q1 		$5.89K Buy
+146
New +$5.46K ﹤0.01% 664

Other funds holding CORT

BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Elevation Wealth Partners's CORT Position: Q2 2026 in Review

Elevation Wealth Partners increased its Corcept Therapeutics (CORT) stake by 21% in Q2 2026, buying an estimated $1.81K and bringing the position to 176 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #669.

Elevation Wealth Partners first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Elevation Wealth Partners held 176 shares of Corcept Therapeutics worth $15.3K as of Q2 2026.
  • Elevation Wealth Partners bought 30 Corcept Therapeutics shares in Q2 2026, an estimated $1.81K.
  • Corcept Therapeutics made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q2 2026, its #669 holding.
  • Elevation Wealth Partners first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.